Anti-Angiogenic Therapy: Current Challenges and Future Perspectives
Open accessThe DOI matches its Crossref record; 242 of the 246 references it cites were found in a registry or an index.
Abstract
Anti-angiogenic therapy is an old method to fight cancer that aims to abolish the nutrient and oxygen supply to the tumor cells through the decrease of the vascular network and the avoidance of new blood vessels formation. Most of the anti-angiogenic agents approved for cancer treatment rely on targeting vascular endothelial growth factor (VEGF) actions, as VEGF signaling is considered the main angiogenesis promotor. In addition to the control of angiogenesis, these drugs can potentiate immune therapy as VEGF also exhibits immunosuppressive functions. Despite the mechanistic rational that strongly supports the benefit of drugs to stop cancer progression, they revealed to be insufficient in most cases. We hypothesize that the rehabilitation of old drugs that interfere with mechanisms of angiogenesis related to tumor microenvironment might represent a promising strategy. In this review, we deepened research on the molecular mechanisms underlying anti-angiogenic strategies and their failure and went further into the alternative mechanisms that impact angiogenesis. We concluded that the combinatory targeting of alternative effectors of angiogenic pathways might be a putative solution for anti-angiogenic therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tyrosine kinase inhibitors (TKIs) have broadened the scope of anti-angiogenic therapy to include other pro-angiogenic growth factors and receptors such as PDGFR, FGFR, c-MET, and PIGF, which are now mainstay targets of the targeted therapy arsenal (Table 2) [33].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [33]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Park, S. Y., Kang, J. H., Jeong, K. J., Lee, J., Han, J. W., Choi, W. S., Kim, Y. K., Kang, J., Park, C. G., & Lee, H. Y. (2011) · International Journal of Cancer · doi:10.1002/ijc.25589 · Cited by 135
RetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Molecular mechanisms and clinical applications of angiogenesis
Carmeliet, P., & Jain, R. K. (2011) · Nature · doi:10.1038/nature10144 · Cited by 5,467 · cited 2×
“The blockage of the VEGF:VEGFR axis seems to be ineffective as monotherapy, and primary or de novo resistance is a common feature in cancer patients [23,123].”
BackgroundCancer drug resistance: an evolving paradigm
Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3599 · Cited by 4,681
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733 · cited 1×
“on tumor growth and an increase in OS [161].”
BackgroundVascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605 · cited 1×
“Moreover, the design and development of new anti-VEGF signaling drugs continues, including the arylamide-5-anilinoquinazoline-8nitro derivative a recent inhibitor of VEGFR2-kinase activity with in vitro anti-tumor and anti-angiogenic activity [38].”
BackgroundFundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Production of large amounts of hydrogen peroxide by human tumor cells.
Szatrowski, T. P., & Nathan, C. (1991) · PubMed · Cited by 3,007
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Wilke, H., Muro, K., Van Cutsem, E., Oh, S.-C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.-Y., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70420-6 · Cited by 2,438 · cited 1×
“PDGF signaling is associated with tumor vascularization in ovarian, non-small-cell lung carcinoma (NSCLC), and hepatocellular carcinoma [79,80].”
BackgroundGiantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279
ROS and the DNA damage response in cancer
Srinivas, U. S., Tan, B. W. Q., Vellayappan, B. A., & Jeyasekharan, A. D. (2019) · Redox Biology · doi:10.1016/j.redox.2018.101084 · Cited by 2,144 · cited 1×
“However, higher ROS are also associated with chemotherapy resistance [221].”
BackgroundDrug Resistance and the Solid Tumor Microenvironment
Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djm135 · Cited by 2,116 · cited 2×
“During this process, the increased proliferation of ECs leads to the formation of a disorganized and immature vascular network with disrupted ECs junctions, pericytes detachment and without a continuous basement membrane, responsible for tumor neo-vessels permeability, interstitial fluid pressure, and fragility [1,2,8…”
BackgroundVascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic Mimicry
Maniotis, A. J., Folberg, R., Hess, A., Seftor, E. A., Gardner, L. M. G., Pe'er, J., Trent, J. M., Meltzer, P. S., & Hendrix, M. J. C. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65173-5 · Cited by 2,043 · cited 2×
“The limited success of the anti-antigenic approaches may be also related to the complexity of tumors vascularization processes, as the angiogenic-like phenomena (see Subsection of Section 1) and the recruitment of EPCs (see Subsection of Section 1) [29,30,34,35].”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
ROS signalling in the biology of cancer
Moloney, J. N., & Cotter, T. G. (2018) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2017.05.023 · Cited by 1,970
VEGF as a Key Mediator of Angiogenesis in Cancer
Carmeliet, P. (2005) · Oncology · doi:10.1159/000088478 · Cited by 1,768
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689 · cited 2×
“During this process, the increased proliferation of ECs leads to the formation of a disorganized and immature vascular network with disrupted ECs junctions, pericytes detachment and without a continuous basement membrane, responsible for tumor neo-vessels permeability, interstitial fluid pressure, and fragility [1,2,8…”
BackgroundPrinciples and mechanisms of vessel normalization for cancer and other angiogenic diseases
Carmeliet, P., & Jain, R. K. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3455 · Cited by 1,675
Casanovas, O., Hicklin, D. J., Bergers, G., & Hanahan, D. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.005 · Cited by 1,621
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Barleon, B., Sozzani, S., Zhou, D., Weich, H., Mantovani, A., & Marme, D. (1996) · Blood · doi:10.1182/blood.v87.8.3336.bloodjournal8783336 · Cited by 1,356
Incalza, M. A., D'Oria, R., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2018) · Vascular Pharmacology · doi:10.1016/j.vph.2017.05.005 · Cited by 1,356 · cited 1×
“pallida and white mulberry (Morus alba) [190].”
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity
Curiel, T. J., Wei, S., Dong, H., Alvarez, X., Cheng, P., Mottram, P., Krzysiek, R., Knutson, K. L., Daniel, B., Zimmermann, M. C., et al. (2003) · Nature Medicine · doi:10.1038/nm863 · Cited by 1,314
Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis
Presta, M., Dell’Era, P., Mitola, S., Moroni, E., Ronca, R., & Rusnati, M. (2005) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2005.01.004 · Cited by 1,261 · cited 1×
“Other studies have been reporting the tumor vessels normalization in hepatocellular carcinoma models and the improved efficacy of VEGF-targeted therapy in ocular disease as outcomes of PIGF blockage [42].”
BackgroundRole of Reactive Oxygen Species in Cancer Progression: Molecular Mechanisms and Recent Advancements
Aggarwal, V., Tuli, H., Varol, A., Thakral, F., Yerer, M., Sak, K., Varol, M., Jain, A., Khan, M., & Sethi, G. (2019) · Biomolecules · doi:10.3390/biom9110735 · Cited by 1,221
Ovarian cancer: strategies for overcoming resistance to chemotherapy
Agarwal, R., & Kaye, S. B. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1123 · Cited by 1,154 · cited 1×
“For instance, forskolin (β-AR agonist) a direct activator of adenylate cyclase that increased AMPc production through β-signaling activation, decreases VEGF-mediated microvessel sprouting while increases were observed with Propranolol, metoprolol, and bisoprolol (2nd generation, β1-AR–selective antagonists), and while…”
BackgroundCycling hypoxia and free radicals regulate angiogenesis and radiotherapy response
Dewhirst, M. W., Cao, Y., & Moeller, B. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2397 · Cited by 1,022
Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Tumor angiogenesis: past, present and the near future
Kerbel, R. S. (2000) · Carcinogenesis · doi:10.1093/carcin/21.3.505 · Cited by 976
Regulatory T cells in tumor immunity
Nishikawa, H., & Sakaguchi, S. (2010) · International Journal of Cancer · doi:10.1002/ijc.25429 · Cited by 944
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Shojaei, F., Wu, X., Malik, A. K., Zhong, C., Baldwin, M. E., Schanz, S., Fuh, G., Gerber, H.-P., & Ferrara, N. (2007) · Nature Biotechnology · doi:10.1038/nbt1323 · Cited by 849
Reactive Oxygen Species: A Key Constituent in Cancer Survival
Kumari, S., Badana, A. K., G, M. M., G, S., & Malla, R. (2018) · Biomarker Insights · doi:10.1177/1177271918755391 · Cited by 777
Targeting the tumour vasculature: insights from physiological angiogenesis
Chung, A. S., Lee, J., & Ferrara, N. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2868 · Cited by 752
Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions
Vasudev, N. S., & Reynolds, A. R. (2014) · Angiogenesis · doi:10.1007/s10456-014-9420-y · Cited by 738 · cited 2×
“However, decades after Folkman’s statement, anti-angiogenic strategies were developed, and antibodies such as bevacizumab are available for cancer therapy [12].”
BackgroundFGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer
Turner, N., Pearson, A., Sharpe, R., Lambros, M., Geyer, F., Lopez-Garcia, M. A., Natrajan, R., Marchio, C., Iorns, E., Mackay, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3746 · Cited by 732 · cited 1×
“In many cancer types, the anti-VEGF resistant tumors present increased expression of FGF and/or FGFR upon hypoxia [45,46] that contributes for the synergistic cooperation of FGF/FGFR and VEFG/VEGFR axes to the amplification of tumor angiogenesis [25].”
BackgroundWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713 · cited 1×
“In both cases, the combination induced a significantly increase in progression free survival (PFS) of cancer patients [149,157].”
BackgroundTumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
Fukumura, D., & Jain, R. K. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.05.003 · Cited by 691
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672 · cited 1×
“Cancer immunotherapy is based on the use of immune checkpoint inhibitors (ICIs) directed against immune checkpoint molecules, vital components of immune homeostasis [146].”
BackgroundMosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood
Chang, Y. S., di Tomaso, E., McDonald, D. M., Jones, R., Jain, R. K., & Munn, L. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14608 · Cited by 671
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Crawford, Y., Kasman, I., Yu, L., Zhong, C., Wu, X., Modrusan, Z., Kaminker, J., & Ferrara, N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.004 · Cited by 611 · cited 1×
“In many cancer types, the anti-VEGF resistant tumors present increased expression of FGF and/or FGFR upon hypoxia [45,46] that contributes for the synergistic cooperation of FGF/FGFR and VEFG/VEGFR axes to the amplification of tumor angiogenesis [25].”
BackgroundSynergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Yi, M., Jiao, D., Qin, S., Chu, Q., Wu, K., & Li, A. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0974-6 · Cited by 608 · cited 1×
“Considering the role of VEGF in the TME, the inhibition of VEGF-induced signaling cascades can ideally suppress tumor growth through two mechanisms: By suppressing angiogenesis and by exerting immunosuppressive effects [20,145].”
BackgroundConsensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P., Alitalo, K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., van Beijnum, J. R., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 590
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585 · cited 1×
“A PARP inhibitor, GPI, was shown to abrogate EC migration and the formation of tube-like structures, thus impairing angiogenesis, without compromising ECs viability, both in vitro and in vivo [235].”
BackgroundPropranolol for Severe Infantile Hemangiomas: Follow-Up Report
Sans, V., de la Roque, E. D., Berge, J., Grenier, N., Boralevi, F., Mazereeuw-Hautier, J., Lipsker, D., Dupuis, E., Ezzedine, K., Vergnes, P., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-3458 · Cited by 568
VEGF Inhibits Tumor Cell Invasion and Mesenchymal Transition through a MET/VEGFR2 Complex
Lu, K. V., Chang, J. P., Parachoniak, C. A., Pandika, M. M., Aghi, M. K., Meyronet, D., Isachenko, N., Fouse, S. D., Phillips, J. J., Cheresh, D. A., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.037 · Cited by 550 · cited 1×
“In cancer models, it was proven that HGF/cMET is responsible for the resistance to anti-VEGF therapy with sunitinib (VEGFR and PDGFR RTKi), while the concomitant exposure to HGF/c-MET inhibitors and sunitinib abrogated angiogenesis and tumor growth [89].”
BackgroundAdrenergic nerves activate an angio-metabolic switch in prostate cancer
Zahalka, A. H., Arnal-Estapé, A., Maryanovich, M., Nakahara, F., Cruz, C. D., Finley, L. W. S., & Frenette, P. S. (2017) · Science · doi:10.1126/science.aah5072 · Cited by 548
Thrombospondin‐1 as an endogenous inhibitor of angiogenesis and tumor growth
Lawler, J. (2002) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2002.tb00307.x · Cited by 540 · cited 1×
“For instance, although ATB-510, a TSP mimetic peptide, in a phase I clinical trial showed a favorable low toxicity profile in patients with various solid tumors [99,100], in a posterior phase II trial in soft tissue sarcoma and stage IV melanoma patients ATB-510 did not show efficacy as a monotherapy, since no improve…”
BackgroundVEGF inhibits T-cell development and may contribute to tumor-induced immune suppression
Ohm, J. E., Gabrilovich, D. I., Sempowski, G. D., Kisseleva, E., Parman, K. S., Nadaf, S., & Carbone, D. P. (2003) · Blood · doi:10.1182/blood-2002-07-1956 · Cited by 538
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Beta Blockers and Breast Cancer Mortality: A Population- Based Study
Barron, T. I., Connolly, R. M., Sharp, L., Bennett, K., & Visvanathan, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.5422 · Cited by 529
Willett, C. G., Duda, D. G., di Tomaso, E., Boucher, Y., Ancukiewicz, M., Sahani, D. V., Lahdenranta, J., Chung, D. C., Fischman, A. J., Lauwers, G. Y., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.1771 · Cited by 508
Kopetz, S., Hoff, P. M., Morris, J. S., Wolff, R. A., Eng, C., Glover, K. Y., Adinin, R., Overman, M. J., Valero, V., Wen, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.8252 · Cited by 485 · cited 1×
“VEGF blockers act on the recognition and neutralization of all bioactive forms of VEGF, preventing VEGFRs activation and consequently inhibiting tumor growth [39].”
BackgroundThe parallel lives of angiogenesis and immunosuppression: cancer and other tales
Motz, G. T., & Coukos, G. (2011) · Nature Reviews Immunology · doi:10.1038/nri3064 · Cited by 481
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Targeting the ANGPT–TIE2 pathway in malignancy
Huang, H., Bhat, A., Woodnutt, G., & Lappe, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2894 · Cited by 468
Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases
Frentzas, S., Simoneau, E., Bridgeman, V. L., Vermeulen, P. B., Foo, S., Kostaras, E., Nathan, M. R., Wotherspoon, A., Gao, Z.-H., Shi, Y., et al. (2016) · Nature Medicine · doi:10.1038/nm.4197 · Cited by 454 · cited 2×
“The limited success of single-targeted monotherapy approaches can be justified by six different mechanisms: (1) The activation of alternative angiogenic signaling pathways; (2) the upregulation of other pro-angiogenic factors [24–28]; (3) the vascular co-option, a process where cancer cells proliferate near the existi…”
BackgroundPowe, D. G., Voss, M. J., Zänker, K. S., Habashy, H. O., Green, A. R., Ellis, I. O., & Entschladen, F. (2010) · Oncotarget · doi:10.18632/oncotarget.197 · Cited by 453
PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
Wu, Y., Chen, W., Xu, Z. P., & Gu, W. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02022 · Cited by 419
The role of the Angiopoietins in vascular morphogenesis
Thomas, M., & Augustin, H. G. (2009) · Angiogenesis · doi:10.1007/s10456-009-9147-3 · Cited by 405 · cited 1×
“alternative as an anti-angiogenesis effective drug [62], involving the downregulation of FGF and VEGF production [63], in multiple myeloma.”
BackgroundBagchi, D., Sen, C. K., Bagchi, M., & Atalay, M. (2004) · Biochemistry (Moscow) · doi:10.1023/b:biry.0000016355.19999.93 · Cited by 404
Human Endothelial Progenitor Cells
Yoder, M. C. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006692 · Cited by 397
Rini, B. I., Michaelson, M. D., Rosenberg, J. E., Bukowski, R. M., Sosman, J. A., Stadler, W. M., Hutson, T. E., Margolin, K., Harmon, C. S., DePrimo, S. E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5416 · Cited by 393 · cited 1×
“Unfortunately, the concomitant use of onartuzumab (anti-c-MET) with bevacizumab brought no additional clinical benefits [91,92].”
BackgroundKloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Duan, J., Cui, L., Zhao, X., Bai, H., Cai, S., Wang, G., Zhao, Z., Zhao, J., Chen, S., Song, J., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.5367 · Cited by 349
Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
Boopathy, G. T. K., & Hong, W. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00049 · Cited by 344 · cited 1×
“Mitochondrial damage, resulting in mitochondrial DNA release to cytosol, is able to dysregulate the Hippo-Yap pathway [239].”
BackgroundEndothelial Cell Metabolism in Health and Disease
Rohlenova, K., Veys, K., Miranda-Santos, I., De Bock, K., & Carmeliet, P. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.10.010 · Cited by 335 · cited 3×
“During this process, the increased proliferation of ECs leads to the formation of a disorganized and immature vascular network with disrupted ECs junctions, pericytes detachment and without a continuous basement membrane, responsible for tumor neo-vessels permeability, interstitial fluid pressure, and fragility [1,2,8…”
BackgroundDuh, E. J., Yang, H. S., Suzuma, I., Miyagi, M., Youngman, E. M., Mori, K., Katai, M., Yan, L., Suzuma, K., West, K. A., et al. (2002) · PubMed · Cited by 326
HGF/c-Met Acts as an Alternative Angiogenic Pathway in Sunitinib-Resistant Tumors
Shojaei, F., Lee, J. H., Simmons, B. H., Wong, A., Esparza, C. O., Plumlee, P. A., Feng, J., Stewart, A. E., Hu-Lowe, D. D., & Christensen, J. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0489 · Cited by 319 · cited 1×
“HGF/c-MET has a role in anti-VEGF therapy resistance and bevacizumab-resistant patients exhibit an upregulation of c-MET expression [88].”
BackgroundExpression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-2
Murdoch, C., Tazzyman, S., Webster, S., & Lewis, C. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.7405 · Cited by 318
Peterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Masiero, M., Simões, F. C., Han, H. D., Snell, C., Peterkin, T., Bridges, E., Mangala, L. S., Wu, S. Y.-Y., Pradeep, S., Li, D., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.004 · Cited by 313 · cited 1×
“During this process, the increased proliferation of ECs leads to the formation of a disorganized and immature vascular network with disrupted ECs junctions, pericytes detachment and without a continuous basement membrane, responsible for tumor neo-vessels permeability, interstitial fluid pressure, and fragility [1,2,8…”
BackgroundTargeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer
André, F., Bachelot, T., Campone, M., Dalenc, F., Perez-Garcia, J. M., Hurvitz, S. A., Turner, N., Rugo, H., Smith, J. W., Deudon, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0190 · Cited by 311 · cited 2×
“For instance, in bevacizumab-resistant tumors, brivanib (dual FGF/VEGF inhibitor) increases the overall survival (OS) in a mouse model of pancreatic neuroendocrine tumor, dovitinib (VEGFR, FGFR and PDGR inhibitor) delays tumor growth, and S49076 (MET, AXL, and FGFR kinase inhibitor) induces tumor growth arrest [47,49,…”
BackgroundAlexandre, J., Batteux, F., Nicco, C., Chéreau, C., Laurent, A., Guillevin, L., Weill, B., & Goldwasser, F. (2006) · International Journal of Cancer · doi:10.1002/ijc.21685 · Cited by 310
ROS-modulated therapeutic approaches in cancer treatment
Raza, M. H., Siraj, S., Arshad, A., Waheed, U., Aldakheel, F., Alduraywish, S., & Arshad, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2464-9 · Cited by 297
Dredge, K., Marriott, J. B., Macdonald, C. D., Man, H.-W., Chen, R., Muller, G. W., Stirling, D., & Dalgleish, A. G. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600607 · Cited by 296 · cited 2×
“Thalidomide is a good and promising example, as the teratogenic effect of thalidomide is due to the prevention of the embryo normal angiogenesis through the interference with FGFs [54].”
BackgroundBhutto, I. A., McLeod, D. S., Hasegawa, T., Kim, S. Y., Merges, C., Tong, P., & Lutty, G. A. (2006) · Experimental Eye Research · doi:10.1016/j.exer.2005.05.007 · Cited by 275 · cited 1×
“The use of PEGF as a drug has been explored, and different phosphomimetic mutants [106,107] and post-translational modified variants [108,109] with enhanced anti-angiogenic activity were already developed.”
BackgroundMartinez-Outschoorn, U. E., Lin, Z., Trimmer, C., Flomenberg, N., Wang, C., Pavlides, S., Pestell, R. G., Howell, A., Sotgia, F., & Lisanti, M. P. (2011) · Cell Cycle · doi:10.4161/cc.10.15.16585 · Cited by 270
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 267 · cited 1×
“For instance, the widely used platinum derivatives, such as carboplatin and cisplatin, increase ROS levels, generating nuclear and mitochondrial DNA adducts [218,219].”
BackgroundMechanism of action in thalidomide teratogenesis
Stephens, T. D., Bunde, C. J. W., & Fillmore, B. J. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00388-3 · Cited by 259
Van de Veire, S., Stalmans, I., Heindryckx, F., Oura, H., Tijeras-Raballand, A., Schmidt, T., Loges, S., Albrecht, I., Jonckx, B., Vinckier, S., et al. (2010) · Cell · doi:10.1016/j.cell.2010.02.039 · Cited by 256
Thalidomide induces limb defects by preventing angiogenic outgrowth during early limb formation
Therapontos, C., Erskine, L., Gardner, E. R., Figg, W. D., & Vargesson, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901505106 · Cited by 254
Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth
Hansen, W., Hutzler, M., Abel, S., Alter, C., Stockmann, C., Kliche, S., Albert, J., Sparwasser, T., Sakaguchi, S., Westendorf, A. M., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111497 · Cited by 250
Ivermectin Induces Cytostatic Autophagy by Blocking the PAK1/Akt Axis in Breast Cancer
Dou, Q., Chen, H.-N., Wang, K., Yuan, K., Lei, Y., Li, K., Lan, J., Chen, Y., Huang, Z., Xie, N., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2887 · Cited by 250
Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
Rigamonti, N., Kadioglu, E., Keklikoglou, I., Wyser Rmili, C., Leow, C. C., & De Palma, M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.06.059 · Cited by 247
Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients
Lutgendorf, S. K., DeGeest, K., Dahmoush, L., Farley, D., Penedo, F., Bender, D., Goodheart, M., Buekers, T. E., Mendez, L., Krueger, G., et al. (2011) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2010.10.012 · Cited by 242 · cited 1×
“The activation of the β-adrenergic system by catecholamines, epinephrine, and norepinephrine has been related to the tumorigenic processes, as cancer cell proliferation and apoptosis, and also with vascular events, as angiogenesis [193,194].”
BackgroundMirza, M. R., Åvall Lundqvist, E., Birrer, M. J., dePont Christensen, R., Nyvang, G.-B., Malander, S., Anttila, M., Werner, T. L., Lund, B., Lindahl, G., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30515-7 · Cited by 242
Tumor angiogenesis and anti‑angiogenic gene therapy for cancer (Review)
Li, T., Kang, G., Wang, T., & Huang, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8733 · Cited by 240 · cited 1×
“The use of a recombinant human endostatin (Endostar) was approved by the State Food and Drug Administration of China in 2005 for the treatment of NSCLC patients [116].”
MethodOlayanju, A., Copple, I. M., Bryan, H. K., Edge, G. T., Sison, R. L., Wong, M. W., Lai, Z.-Q., Lin, Z.-X., Dunn, K., Sanderson, C. M., et al. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.11.003 · Cited by 232
Huang, Y., Chen, X., Dikov, M. M., Novitskiy, S. V., Mosse, C. A., Yang, L., & Carbone, D. P. (2007) · Blood · doi:10.1182/blood-2007-01-065714 · Cited by 230
Sastry, K. S. R., Karpova, Y., Prokopovich, S., Smith, A. J., Essau, B., Gersappe, A., Carson, J. P., Weber, M. J., Register, T. C., Chen, Y. Q., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611370200 · Cited by 229 · cited 1×
“In ovarian cancer patients under social isolation, the increased levels of noradrenaline are correlated with tumor grade and stage, suggesting the contribution of the β-adrenergic receptors (β-AR) system in cancer progression [195].”
BackgroundThrombospondins function as regulators of angiogenesis
Bornstein, P. (2009) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-009-0060-8 · Cited by 223 · cited 2×
“Given that and considering that the expression of those factors in tumors is often low, there was an increasing interest in the application of these factors and its derivatives as potential anticancer agents [97].”
BackgroundAngiopoietins in tumours: the angiogenic switch
Tait, C. R., & Jones, P. F. (2004) · The Journal of Pathology · doi:10.1002/path.1618 · Cited by 223 · cited 1×
“The angiogenic pattern activated by ANG2 resembles the cancer angiogenesis, which is characterized by unstable and leakier vessels [69].”
BackgroundR Regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways
Cao, Y., Cao, R., & Hedlund, E.-M. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-008-0337-z · Cited by 215
Alfaro, C., Suarez, N., Gonzalez, A., Solano, S., Erro, L., Dubrot, J., Palazon, A., Hervas-Stubbs, S., Gurpide, A., Lopez-Picazo, J. M., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604965 · Cited by 214
Rini, B. I., Bellmunt, J., Clancy, J., Wang, K., Niethammer, A. G., Hariharan, S., & Escudier, B. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.5305 · Cited by 212
The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential
Becerra, S. P., & Notario, V. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3484 · Cited by 211 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundHaanen, J. B. A. G., & Robert, C. (2015) · Progress in Tumor Research · doi:10.1159/000437178 · Cited by 208 · cited 1×
“Their blockade results in the removal of inhibitory signals of T-cell activation, enhancing anti-tumor immune activity and leading to the inhibition of tumor growth, through CD8+ T-cell mediated cancer cells death [150,151].”
BackgroundHermes, G. L., Delgado, B., Tretiakova, M., Cavigelli, S. A., Krausz, T., Conzen, S. D., & McClintock, M. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910753106 · Cited by 207
Jahangiri, A., De Lay, M., Miller, L. M., Carbonell, W. S., Hu, Y.-L., Lu, K., Tom, M. W., Paquette, J., Tokuyasu, T. A., Tsao, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1281 · Cited by 202 · cited 1×
“In a cancer context, HGF/c-MET activation exerts pro-angiogenic effects, leading to a direct activation of ECs and an indirect stimulation of other pro-angiogenic factors, as VEGF [87].”
BackgroundAngiopoietin–Tie signalling in the cardiovascular and lymphatic systems
Eklund, L., Kangas, J., & Saharinen, P. (2017) · Clinical Science · doi:10.1042/cs20160129 · Cited by 202
Ponatinib: a novel multi-tyrosine kinase inhibitor against human malignancies
Tan, F. H., Putoczki, T. L., Stylli, S. S., & Luwor, R. B. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189391 · Cited by 200 · cited 1×
“In the future, the use of PDGF inhibitors might have a place in the portfolio of therapeutic options for the improvement of clinical efficacy of VEGF blockers [84,85].”
BackgroundImmunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Wu, Y., Hooper, A. T., Zhong, Z., Witte, L., Bohlen, P., Rafii, S., & Hicklin, D. J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21865 · Cited by 192
THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Catalytic receptors
Alexander, S. P. H., Fabbro, D., Kelly, E., Mathie, A., Peters, J. A., Veale, E. L., Armstrong, J. F., Faccenda, E., Harding, S. D., Pawson, A. J., et al. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14751 · Cited by 192 · cited 1×
“FGFs are known as potent angiogenic inducers that increase the proliferation and the migration of ECs [43].”
BackgroundSun, L., Zhang, L., Yu, J., Zhang, Y., Pang, X., Ma, C., Shen, M., Ruan, S., Wasan, H. S., & Qiu, S. (2020) · Scientific Reports · doi:10.1038/s41598-020-58674-4 · Cited by 192
Multifarious functions of PDGFs and PDGFRs in tumor growth and metastasis
Cao, Y. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.05.002 · Cited by 190
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
You, W.-K., & McDonald, D. M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.12.833 · Cited by 190 · cited 1×
“In the future, the use of PDGF inhibitors might have a place in the portfolio of therapeutic options for the improvement of clinical efficacy of VEGF blockers [84,85].”
BackgroundBellon, J. R., Come, S. E., Gelman, R. S., Henderson, I. C., Shulman, L. N., Silver, B. J., Harris, J. R., & Recht, A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.032 · Cited by 188 · cited 1×
“Despite being tested in clinical trials since 2002 [119], further clinical studies are needed to confirm its safety and to better understand endostatin mechanism of action and efficacy, since its effects are complex and may interfere with several different mechanisms [115].”
Goede, V, Coutelle, O., Neuneier, J., Reinacher-Schick, A., Schnell, R., Koslowsky, T. C., Weihrauch, M. R., Cremer, B., Kashkar, H., Odenthal, M., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605925 · Cited by 186
Pahler, J. C., Tazzyman, S., Erez, N., Chen, Y.-Y., Murdoch, C., Nozawa, H., Lewis, C. E., & Hanahan, D. (2008) · Neoplasia · doi:10.1593/neo.07871 · Cited by 184 · cited 2×
“The limited success of single-targeted monotherapy approaches can be justified by six different mechanisms: (1) The activation of alternative angiogenic signaling pathways; (2) the upregulation of other pro-angiogenic factors [24–28]; (3) the vascular co-option, a process where cancer cells proliferate near the existi…”
BackgroundPotential Applications of NRF2 Inhibitors in Cancer Therapy
Panieri, E., & Saso, L. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8592348 · Cited by 184 · cited 2×
“Several Nrf2 inhibitors have been studied in the context of cancer therapy, as reviewed in Panieri and Saso, 2019 [227], including brusatol, a quassinoid compound extracted from Brucea javanica that was shown to deplete Nrf2 protein levels in mouse hepatoma cells [228].”
BackgroundEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications
Walia, A., Yang, J. F., Huang, Y.-H., Rosenblatt, M. I., Chang, J.-H., & Azar, D. T. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.09.007 · Cited by 182 · cited 1×
“Endostatin is a C-terminal fragment of type XVIII collagen and it is the strongest endogenous inhibitor of angiogenesis [114,115], its use in cancer therapy being a promising tool.”
BackgroundPARP Inhibition in Cancer: An Update on Clinical Development
Sachdev, E., Tabatabai, R., Roy, V., Rimel, B. J., & Mita, M. M. (2019) · Targeted Oncology · doi:10.1007/s11523-019-00680-2 · Cited by 179 · cited 1×
“This effect occurred not only in a hypoxic context, in which hypoxia is able to inhibit HDR by several mechanisms [233], but also in normoxic conditions through the down-regulation of BRCA1/2 and RAD51 genes [232].”
BackgroundDraganov, D., Gopalakrishna-Pillai, S., Chen, Y.-R., Zuckerman, N., Moeller, S., Wang, C., Ann, D., & Lee, P. P. (2015) · Scientific Reports · doi:10.1038/srep16222 · Cited by 174
和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 169
Mikuła-Pietrasik, J., Witucka, A., Pakuła, M., Uruski, P., Begier-Krasińska, B., Niklas, A., Tykarski, A., & Książek, K. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2954-1 · Cited by 169 · cited 1×
“For instance, the widely used platinum derivatives, such as carboplatin and cisplatin, increase ROS levels, generating nuclear and mitochondrial DNA adducts [218,219].”
BackgroundGavalas, N. G., Tsiatas, M., Tsitsilonis, O., Politi, E., Ioannou, K., Ziogas, A. C., Rodolakis, A., Vlahos, G., Thomakos, N., Haidopoulos, D., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.468 · Cited by 167
Pasquier, E., Street, J., Pouchy, C., Carre, M., Gifford, A. J., Murray, J., Norris, M. D., Trahair, T., Andre, N., & Kavallaris, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.205 · Cited by 162
Successful Treatment of an Angiogenic Disease
Folkman, J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198905043201811 · Cited by 162
Yuan, L., Mao, Y., Luo, W., Wu, W., Xu, H., Wang, X. L., & Shen, Y. H. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.804005 · Cited by 161
Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis
Tentori, L., Lacal, P. M., Muzi, A., Dorio, A. S., Leonetti, C., Scarsella, M., Ruffini, F., Xu, W., Min, W., Stoppacciaro, A., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.07.010 · Cited by 159
Nicotine Promotes Colon Tumor Growth and Angiogenesis through -Adrenergic Activation
Wong, H. P. S., Yu, L., Lam, E. K. Y., Tai, E. K. K., Wu, W. K. K., & Cho, C.-H. (2007) · Toxicological Sciences · doi:10.1093/toxsci/kfm060 · Cited by 159
The differential role of reactive oxygen species in early and late stages of cancer
Assi, M. (2017) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00247.2017 · Cited by 158 · cited 1×
“Moreover, in human colon carcinoma cells, the mutant p53 triggers angiogenesis through the ROS-mediated activation of VEGF and HiF1α [177].”
BackgroundCediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51
Kaplan, A. R., Gueble, S. E., Liu, Y., Oeck, S., Kim, H., Yun, Z., & Glazer, P. M. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4508 · Cited by 158
Propranolol Induces Regression of Hemangioma Cells Through HIF-1α–Mediated Inhibition of VEGF-A
Chim, H., Armijo, B. S., Miller, E. E., Gliniak, C. M., Serret, M. A., & Gosain, A. K. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e318254ce7a · Cited by 157
Molecular mechanisms of tumor vascularization
Auguste, P., Lemière, S., Larrieu-Lahargue, F., & Bikfalvi, A. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.11.006 · Cited by 156
Wu, Y. L., Zhong, Z., Huber, J., Bassi, R., Finnerty, B., Corcoran, E., Li, H., Navarro, E. C., Balderes, P. J., Jimenez, X., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0831 · Cited by 156 · cited 1×
“Considering the role of VEGF in the TME, the inhibition of VEGF-induced signaling cascades can ideally suppress tumor growth through two mechanisms: By suppressing angiogenesis and by exerting immunosuppressive effects [20,145].”
BackgroundHe, X., Cheng, R., Benyajati, S., & Ma, J.-X. (2015) · Clinical Science · doi:10.1042/cs20130463 · Cited by 151 · cited 1×
“Likewise, a recombinant version of the three thrombospondin repeat (TSR) domains designated 3TSR was shown to normalize tumor vasculature and to potentiate the tumor regression mediated by chemotherapy [104], reinforcing that a stable vasculature potentiates the anti-cancer therapy by allowing a more effective drug de…”
BackgroundLiu, T., Ma, W., Xu, H., Huang, M., Zhang, D., He, Z., Zhang, L., Brem, S., O’Rourke, D. M., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05982-z · Cited by 151 · cited 1×
“In glioblastoma, the increased expression of PDGFR is related to poor prognosis [81], and the dual inhibition of VEGF/PDGFR improves survival in mice models [81,82].”
BackgroundAllen, E., Walters, I. B., & Hanahan, D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2847 · Cited by 147 · cited 1×
“In many cancer types, the anti-VEGF resistant tumors present increased expression of FGF and/or FGFR upon hypoxia [45,46] that contributes for the synergistic cooperation of FGF/FGFR and VEFG/VEGFR axes to the amplification of tumor angiogenesis [25].”
BackgroundPastukh, V., Roberts, J. T., Clark, D. W., Bardwell, G. C., Patel, M., Al-Mehdi, A.-B., Borchert, G. M., & Gillespie, M. N. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00236.2015 · Cited by 147 · cited 1×
“Even though these are promising results, it is important to note that some controversy remains on the impact of NRF2 pharmacological modulation on tumor growth [230].”
BackgroundToth, R. K., & Warfel, N. A. (2017) · Antioxidants · doi:10.3390/antiox6020027 · Cited by 147
Cloughesy, T., Finocchiaro, G., Belda-Iniesta, C., Recht, L., Brandes, A. A., Pineda, E., Mikkelsen, T., Chinot, O. L., Balana, C., Macdonald, D. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.7685 · Cited by 146
Controversy about pharmacological modulation of Nrf2 for cancer therapy
Milkovic, L., Zarkovic, N., & Saso, L. (2017) · Redox Biology · doi:10.1016/j.redox.2017.04.013 · Cited by 142
Thrombospondin-based antiangiogenic therapy
Zhang, X., & Lawler, J. (2007) · Microvascular Research · doi:10.1016/j.mvr.2007.04.007 · Cited by 141 · cited 1×
“Moreover, aflibercept (or ziv-aflibercept), a drug that neutralizes both VEGF and PIGF, showed to be effective in cancer patients-derived xenografts models [96].”
BackgroundRedox-Mediated Mechanism of Chemoresistance in Cancer Cells
Kim, E.-K., Jang, M., Song, M.-J., Kim, D., Kim, Y., & Jang, H. H. (2019) · Antioxidants · doi:10.3390/antiox8100471 · Cited by 141 · cited 1×
“These adducts are then recognized by DNA damage repair pathways, triggering apoptosis [220].”
BackgroundFukui, M., Yamabe, N., & Zhu, B. T. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.004 · Cited by 140 · cited 1×
“The in vitro exposure of breast cancer cells to the antioxidant resveratrol reduce the ROS accumulation, decreasing paclitaxel-induced cell death [183,184].”
BackgroundWojta, J., Kaun, C., Breuss, J. M., Koshelnick, Y., Beckmann, R., Hattey, E., Mildner, M., Weninger, W., Nakamura, T., Tschachler, E., et al. (1999) · PubMed · Cited by 139
Tumor–stroma co-evolution in prostate cancer progression and metastasis
Josson, S., Matsuoka, Y., Chung, L. W. K., Zhau, H. E., & Wang, R. (2010) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2009.11.016 · Cited by 137
Angara, K., Borin, T. F., & Arbab, A. S. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.04.007 · Cited by 137
The enigmatic role of angiopoietin-1 in tumor angiogenesis
Metheny‐Barlow, L. J., & Lu Yuan, L. I. (2003) · Cell Research · doi:10.1038/sj.cr.7290176 · Cited by 135
Vasculogenic Mimicry: Become an Endothelial Cell “But Not So Much”
Fernández‐Cortés, M., Delgado‐Bellido, D., & Oliver, F. J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00803 · Cited by 134
Lieu, C. H., Tran, H., Jiang, Z.-Q., Mao, M., Overman, M. J., Lin, E., Eng, C., Morris, J., Ellis, L., Heymach, J. V., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077117 · Cited by 127 · cited 2×
“For instance, in metastatic colorectal cancer patients, bevacizumab was associated with increased plasma levels of placental growth factor (PIGF), FGF, and platelet-derived growth factor (PDGF), prior or along disease progression [40,41].”
BackgroundPotential Contributions of Antioxidants to Cancer Therapy: Immunomodulation and Radiosensitization
Thyagarajan, A., & Sahu, R. P. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735416681639 · Cited by 126
Jayakumar, S., Pal, D., & Sandur, S. K. (2015) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2015.06.007 · Cited by 124
Silva, M. M., Rocha, C. R. R., Kinker, G. S., Pelegrini, A. L., & Menck, C. F. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-54065-6 · Cited by 120 · cited 1×
“More recently, the role of Nrf2 in DNA damage repair has been explored, and some studies have already shown a potential protective effect of Nrf2 in chemotherapy and radiotherapyinduced DNA damage [224].”
BackgroundCompensatory angiogenesis and tumor refractoriness
Gacche, R. N. (2015) · Oncogenesis · doi:10.1038/oncsis.2015.14 · Cited by 111
Liu, Y., Fang, S., Sun, Q., & Liu, B. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.064 · Cited by 111
Хромова, Н. В., Kopnin, P., Степанова, Е. В., Agapova, L. S., & Kopnin, B. P. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.10.049 · Cited by 110 · cited 1×
“The generation of ROS levels in cancer cells prompted by 27-hydroxycholesterol (27HC) and deferoxamine (DFO) activates STAT-3/VEGF and ERK1/2/HIF1α signaling pathways, promoting tumor angiogenesis and metastasis [175,176].”
BackgroundFagiani, E., Lorentz, P., Kopfstein, L., & Christofori, G. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4635 · Cited by 110 · cited 1×
“On the contrary, ANG2 (mostly produced by ECs) acts as an endogenous antagonist of ANG1 function that leads to remodeling processes or vascular sprouting in response to VEGF [68].”
BackgroundAnti-angiogenic properties of carnosol and carnosic acid, two major dietary compounds from rosemary
López-Jiménez, A., García‐Caballero, M., Medina, M. Á., & Quesada, A. R. (2011) · European Journal of Nutrition · doi:10.1007/s00394-011-0289-x · Cited by 109
A Phase II Study of ABT-510 (Thrombospondin-1 Analog) for the Treatment of Metastatic Melanoma
Markovic, S. N., Suman, V. J., Rao, R. A., Ingle, J. N., Kaur, J. S., Erickson, L. A., Pitot, H. C., Croghan, G. A., McWilliams, R. R., Merchan, J., et al. (2007) · American Journal of Clinical Oncology · doi:10.1097/01.coc.0000256104.80089.35 · Cited by 109
Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword?
Cascone, T., & Heymach, J. V. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7621 · Cited by 108 · cited 1×
“However, ANG1 also seems to limit the continuous angiogenesis in the tumor and consequently contribute for tumor growth inhibition [67].”
BackgroundAnti-tumor and anti-angiogenic effects of Fucoidan on prostate cancer: possible JAK-STAT3 pathway
Xin, R., Pan, H., Shao, S., & Xu, X. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-017-1885-y · Cited by 107
Catecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages
Xia, Y., Wei, Y., Li, Z.-Y., Cai, X.-Y., Zhang, L.-L., Dong, X.-R., Zhang, S., Zhang, R.-G., Meng, R., Zhu, F., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.004 · Cited by 103 · cited 1×
“Propranolol demonstrated anti-cancer and anti-angiogenic pharmacological properties since its administration in breast cancer patients with arterial hypertension significantly reduced the primary tumor development, nodal/metastatic occurrence, and breast cancer-specific mortality [209]; abrogated the VEGF production […”
BackgroundHidalgo, M., Martinez-Garcia, M., Le Tourneau, C., Massard, C., Garralda, E., Boni, V., Taus, A., Albanell, J., Sablin, M.-P., Alt, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1588 · Cited by 102
NRF2 preserves genomic integrity by facilitating ATR activation and G2 cell cycle arrest
Sun, X., Wang, Y., Ji, K., Liu, Y., Kong, Y., Nie, S., Li, N., Hao, J., Xie, Y., Xu, C., et al. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa631 · Cited by 101 · cited 2×
“This transcription factor is the major one responsible for the redox balance, controlling the expression of antioxidant-response genes [223].”
BackgroundImpact of hypoxia on DNA repair and genome integrity
Kaplan, A. R., & Glazer, P. M. (2019) · Mutagenesis · doi:10.1093/mutage/gez019 · Cited by 99 · cited 3×
“This pathway is a key inhibitor of angiogenesis [231,232].”
BackgroundHoekstra, R., de Vos, F. Y. F. L., Eskens, F. A. L. M., Gietema, J. A., van der Gaast, A., Groen, H. J. M., Knight, R. A., Carr, R. A., Humerickhouse, R. A., Verweij, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.013 · Cited by 98 · cited 1×
“TSP is amongst the first described angiogenesis inhibitors [98], and different attempts were already made to validate TSP and analogs as anti-angiogenic modulators for therapeutic use.”
BackgroundHulsurkar, M. M., Li, Z., Zhang, Y., Li, X., Zheng, D., & Li, W. (2016) · Oncogene · doi:10.1038/onc.2016.319 · Cited by 98
Cantanhede, I. G., & de Oliveira, J. R. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-15045-w · Cited by 95
Biaoxue, R., Shuanying, Y., Li, W., Zhang, W., & Zongjuan, M. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-170 · Cited by 94 · cited 2×
“Despite being tested in clinical trials since 2002 [119], further clinical studies are needed to confirm its safety and to better understand endostatin mechanism of action and efficacy, since its effects are complex and may interfere with several different mechanisms [115].”
BackgroundBurbridge, M. F., Bossard, C. J., Saunier, C., Fejes, I., Bruno, A., Léonce, S., Ferry, G., Da Violante, G., Bouzom, F., Cattan, V., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0075 · Cited by 90
Schuller, H. M., Al-Wadei, H. A. N., Ullah, M. F., & Plummer, H. K. (2012) · Carcinogenesis · doi:10.1093/carcin/bgr251 · Cited by 90
de Aguiar, R. B., & de Moraes, J. Z. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01023 · Cited by 88 · cited 1×
“showed that the knockout of NRP1 in Foxp3+ Tregs reduced Tregs infiltration into the TME, while it increased CD8+ cytotoxic T-cells, leading to prolonged survival in melanoma bearing mice [143,144].”
BackgroundBaker, L. H., Rowinsky, E. K., Mendelson, D., Humerickhouse, R. A., Knight, R. A., Qian, J., Carr, R. A., Gordon, G. B., & Demetri, G. D. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.4706 · Cited by 87
Baicalein inhibits oxidative stress-induced cellular damage via antioxidant effects
Kang, K. A., Zhang, R., Piao, M. J., Chae, S., Kim, H. S., Park, J. H., Jung, K. S., & Hyun, J. W. (2011) · Toxicology and Industrial Health · doi:10.1177/0748233711413799 · Cited by 87
Li, D., Xie, K., Zhang, L., Yao, X., Li, H., Xu, Q., Wang, X., Jiang, J., & Fang, J. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.04.036 · Cited by 87 · cited 1×
“The limited success of single-targeted monotherapy approaches can be justified by six different mechanisms: (1) The activation of alternative angiogenic signaling pathways; (2) the upregulation of other pro-angiogenic factors [24–28]; (3) the vascular co-option, a process where cancer cells proliferate near the existi…”
BackgroundAdrenergic signaling promotes angiogenesis through endothelial cell-tumor cell crosstalk
Chen, H., Liu, D., Yang, Z., Sun, L., Deng, Q., Yang, S., Qian, L., Guo, L., Yu, M., Hu, M., et al. (2014) · Endocrine Related Cancer · doi:10.1530/erc-14-0236 · Cited by 86 · cited 1×
“, pancreatic, lung, colon) are able to synthesize and release adrenaline [201,202].”
BackgroundPonatinib: A Review of Efficacy and Safety
Massaro, F., Molica, M., & Breccia, M. (2017) · Current Cancer Drug Targets · doi:10.2174/1568009617666171002142659 · Cited by 83 · cited 1×
“In vitro, ponatinib, a multi-tyrosine kinase inhibitor including PDGFR inhibitor, reduces the viability, migration, and tube forming capacity of human umbilical vein ECs (HUVECs) [83].”
BackgroundMercurio, A., Adriani, G., Catalano, A., Carocci, A., Rao, L., Lentini, G., Cavalluzzi, M. M., Franchini, C., Vacca, A., & Corbo, F. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170601074646 · Cited by 81
Four, S. D., Maenhout, S. K., Niclou, S. P., Thielemans, K., Neyns, B., & Aerts, J. L. (2016) · PubMed · Cited by 80
Effects of adrenaline in human colon adenocarcinoma HT-29 cells
Wong, H. P. S., Ho, J. W. C., Koo, M. W. L., Yu, L., Wu, W. K. K., Lam, E. K. Y., Tai, E. K. K., Ko, J. K.-S., Shin, V. Y., Chu, K., et al. (2011) · Life Sciences · doi:10.1016/j.lfs.2011.04.007 · Cited by 79
Vitamin C suppresses cell death in MCF ‐7 human breast cancer cells induced by tamoxifen
Subramani, T., Yeap, S. K., Ho, W. Y., Ho, C. L., Omar, A. R., Aziz, S. A., Rahman, N. M. A. N. A., & Alitheen, N. B. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12188 · Cited by 79
Lu, Y., Wang, B., Shi, Q., Wang, X., Wang, D., & Zhu, L. (2016) · Scientific Reports · doi:10.1038/srep39123 · Cited by 76
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
Michaelsen, S. R., Staberg, M., Pedersen, H., Jensen, K. E., Majewski, W. W., Broholm, H., Nedergaard, M. K., Meulengracht, C., Urup, T. H., Villingshøj, M., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy103 · Cited by 76
Qiang, H., Chang, Q., Xu, J., Qian, J., Zhang, Y., Lei, Y., Han, B., & Chu, T. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03129-6 · Cited by 76 · cited 2×
“A phase III clinical trial (IMpower150) reported a significant improvement of PFS and OS in metastatic non-squamous subset of NSCLC patients after the combined administration of atezolizumab, bevacizumab, and chemotherapy (carboplatin and paclitaxel) [162].”
BackgroundBelkacemi, L., & Zhang, S. X. (2016) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-015-0278-7 · Cited by 73 · cited 1×
“These strategies have focused mainly on eye disease [110] and wound healing [111], but their application in cancer therapy is under debate [112,113].”
BackgroundBiologic Effects of Dopamine on Tumor Vasculature in Ovarian Carcinoma
Moreno-Smith, M., Lee, S. J., Lu, C., Nagaraja, A. S., He, G., Rupaimoole, R., Han, H. D., Jennings, N. B., Roh, J.-W., Nishimura, M., et al. (2013) · Neoplasia · doi:10.1593/neo.121412 · Cited by 72 · cited 1×
“The crosstalk between ECs and cancer cells potentiates tumor angiogenesis mediated by β-AR signaling pathway, inducing the EC activation of Jagged1/Notch intercellular signaling and the metabolic shift of ECs from oxidative phosphorylation to aerobic glycolysis, which represents a critical step during the angiogenic s…”
BackgroundPonatinib reduces viability, migration, and functionality of human endothelial cells
Gover‐Proaktor, A., Granot, G., Shapira, S., Raz, O., Pasvolsky, O., Nagler, A., Lev, D., Inbal, A., Lubin, I., Raanani, P., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1239258 · Cited by 70 · cited 1×
“In glioblastoma, the increased expression of PDGFR is related to poor prognosis [81], and the dual inhibition of VEGF/PDGFR improves survival in mice models [81,82].”
BackgroundRussell, S. J., Duquette, M. A., Liu, J. F., Drapkin, R., Lawler, J., & Petrik, J. (2014) · The FASEB Journal · doi:10.1096/fj.14-261636 · Cited by 69
The scientific contributions of M. Judah Folkman to cancer research
Zetter, B. R. (2008) · Nature reviews. Cancer · doi:10.1038/nrc2458 · Cited by 69
Zhu, D., Shen, Z., Liu, J., Chen, J., Liu, Y., Hu, C., Li, Z., & Li, Y. (2016) · Toxicology Letters · doi:10.1016/j.toxlet.2016.11.006 · Cited by 69
Liu, Y., Cui, Y., Shi, M., Zhang, Q., Wang, Q., & Chen, X. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000358674 · Cited by 68
Chiron, M., Bagley, R. G., Pollard, J., Mankoo, P. K., Henry, C., Vincent, L., Geslin, C., Baltes, N., & Bergstrom, D. A. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0753 · Cited by 68
Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
Li, K., Shi, M., & Qin, S. (2018) · Oncology and Therapy · doi:10.1007/s40487-017-0055-1 · Cited by 67 · cited 1×
“Since then, several studies have been relating the anti-cancer properties of this therapy for a variety of other cancer types, including colorectal cancer, melanoma, and breast cancer, whether as a monotherapy or in combination [117,118].”
BackgroundNorden, A. D., Schiff, D., Ahluwalia, M. S., Lesser, G. J., Nayak, L., Lee, E. Q., Rinne, M. L., Muzikansky, A., Dietrich, J., Purow, B. W., et al. (2014) · Journal of Neuro-Oncology · doi:10.1007/s11060-014-1631-y · Cited by 65 · cited 2×
“For instance, in bevacizumab-resistant tumors, brivanib (dual FGF/VEGF inhibitor) increases the overall survival (OS) in a mouse model of pancreatic neuroendocrine tumor, dovitinib (VEGFR, FGFR and PDGR inhibitor) delays tumor growth, and S49076 (MET, AXL, and FGFR kinase inhibitor) induces tumor growth arrest [47,49,…”
BackgroundAlam, A. K., Hossain, A. S., Khan, M. A., Kabir, S. R., Reza, M. A., Rahman, M. M., Islam, M. S., Rahman, M. A. A., Rashid, M., & Sadik, G. (2016) · PLoS ONE · doi:10.1371/journal.pone.0167536 · Cited by 64
Argentiero, A., Solimando, A. G., Krebs, M., Leone, P., Susca, N., Brunetti, O., Racanelli, V., Vacca, A., & Silvestris, N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9051594 · Cited by 64
R0 resection in the treatment of gastric cancer: Room for improvement
Biondi, A. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i27.3358 · Cited by 63
Maik-Rachline, G., Shaltiel, S., & Seger, R. (2004) · Blood · doi:10.1182/blood-2004-04-1569 · Cited by 62 · cited 1×
“PEDF is a multifunctional member of the serine proteinase inhibitor (serpin) family and it plays a role as an inhibitor of angiogenesis [105].”
BackgroundTumor resistance to anti-VEGF therapy through up-regulation of VEGF-C expression
Li, D., Xie, K., Ding, G., Li, J., Chen, K., Li, H., Qian, J., Jiang, C., & Fang, J. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.004 · Cited by 62
Catecholamines in the regulation of angiogenesis in cutaneous wound healing
Chakroborty, D., Goswami, S., Basu, S., & Sarkar, C. (2020) · The FASEB Journal · doi:10.1096/fj.202001701r · Cited by 60
Nabors, L. B., Fiveash, J. B., Markert, J. M., Kekan, M. S., Gillespie, G. Y., Huang, Z., Johnson, M. J., Meleth, S., Kuo, H., Gladson, C. L., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.16 · Cited by 59 · cited 1×
“For instance, although ATB-510, a TSP mimetic peptide, in a phase I clinical trial showed a favorable low toxicity profile in patients with various solid tumors [99,100], in a posterior phase II trial in soft tissue sarcoma and stage IV melanoma patients ATB-510 did not show efficacy as a monotherapy, since no improve…”
Background
Research works printed but not linked: 1
- Domingues, G., Fernandes, S.G., and Serpa, J. (2015). Dynamics of VEGF-A and its Receptors in Cancer Vascularization—An Overview. Understand Cancer: Research and Treatment, iConcept Press. Chapter 3.
Cited by
The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF
Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175586 · Cited by 362
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
VEGF signaling: Role in angiogenesis and beyond
Shaw, P., Dwivedi, S. K. D., Bhattacharya, R., Mukherjee, P., & Rao, G. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189079 · Cited by 215
Fang, J., Lu, Y., Zheng, J., Jiang, X., Shen, H., Shang, X., Lu, Y., & Fu, P. (2023) · Cell Death & Disease · doi:10.1038/s41419-023-06119-x · Cited by 209
“Most of these agents disrupt the VEGF signaling pathways involved in ECs proliferation and migration, effectively impeding tumor growth [221].”
BackgroundPatil, T. P., Vibhute, A., Patil, S. L., Dongale, T. D., & Pandey-Tiwari, A. (2023) · Applied Surface Science Advances · doi:10.1016/j.apsadv.2023.100372 · Cited by 135
Metadata
- Authors
- Lopes-Coelho, F., Martins, F., Pereira, S. A., & Serpa, J.
- Affiliations
- Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof. Lima Basto, 1099-023 Lisboa, Portugal
- Instituto Português de Oncologia Francisco Gentil (PT)
- Universidade Nova de Lisboa (PT)
- Corresponding author
- Serpa, Jacinta
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-04-05
- Volume
- 22
- Issue
- 7
- Pages
- 3765
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC8038573
- OpenAlex
- W3140967360
- Cited by
- 416
- References
- 246
- Citations by year
- 2026: 61 · 2025: 98 · 2024: 117 · 2023: 86 · 2022: 46 · 2021: 8
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministério da Educação e Ciência
- Ministério da Ciência, Tecnologia e Ensino Superior
- Ministério da Educação
- Fundação para a Ciência e a Tecnologia (/2017, iNOVA4Health, PD/BD/128337/2017)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- anti-angiogenic therapy, angiogenesis, VEGF signaling, tumor microenvironment, cancer immunotherapy, immunosuppression, drug repurposing, combination therapy, tumor vasculature, treatment resistance
- MeSH terms
- Animals, Humans, Neoplasm Proteins, Neoplasms, Neovascularization, Pathologic, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.